FDA Brief

Warning letters Drugs

FDA warning letter to

BRS Analytical Services, LLC

High riskIssued Sep 17, 2025Posted Oct 21, 2025Center for Drug Evaluation and Research (CDER)

BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.

What happened

FDA inspected BRS Analytical Services, LLC's drug manufacturing facility and contract testing laboratory in St. Louis, MO, from March 10 to 26, 2025. Investigators found an aseptic cleanroom with gaps to a warehouse outside the cleanroom, inadequate pressure control and environmental monitoring, poor aseptic practices, inadequate media fills and sterilization validation, and a smoke study that did not show unidirectional airflow. On April 23, 2025, BRS recalled all sterile OTC drug products due to current good manufacturing practice (CGMP) deviations and lack of sterility assurance, and it committed to cease production.

What FDA found

  1. The aseptic cleanroom was not properly separated from the warehouse; there were gaps in walls and floors, and pressure was not maintained or continuously monitored.

    21 CFR 211.42(c)(10) and 211.63
  2. Environmental monitoring was inadequate: viable air was not routinely monitored, the particle monitor was outside the filling cabinet, and data were not reviewed before batch release.

    21 CFR 211.42(c)(10)
  3. Operators used poor aseptic practices, including blocking airflow over open bottles, exposing skin, using nonsterile masks and paper towels, and not sealing a vessel of sterile drug product.

    21 CFR 211.113(b)
  4. Media fills used to simulate filling did not mimic commercial operations because too few units were incubated and the runs were too short.

    21 CFR 211.113(b)
  5. Sterilization validation was inadequate and sterilizing filters were not integrity tested for each batch; a water sample tested positive but was not investigated.

    21 CFR 211.113(b)
  6. The quality unit failed to provide adequate CGMP oversight and allowed distribution of sterile drugs made under unacceptable conditions, and supplier qualification procedures were inadequate.

    21 CFR 211.22

What FDA wants

FDA asks BRS to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, and to give reasons and a completion schedule if it cannot finish within that time. FDA also asks the firm to notify it before resuming drug manufacturing and recommends a qualified CGMP consultant.

Who should pay attention

  • companies that bought or distributed BRS sterile OTC drugs
  • contract manufacturers and testing labs using aseptic processing
  • brands relying on outside sterile manufacturing or testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk